Laplace Interventional, a Minneapolis, MN-based medical device company, raised $12.9M in Series B funding.
The round was led by ShangBay Capital along with Features Capital in addition to participation from Engage Venture Partners, JWC Ventures. Laplace also announced that Jenny Barba, Co-Founder and Managing Partner at Features Capital, joined its Board of Directors and Todd Mortier, a serial MedTech entrepreneur had previously joined its Board of Directors.
The company intends to use the funds to pursue their First-in-Human (FIH) and clinical feasibility evaluation of its transcatheter valve system.
Led by Ramji Iyer, Founder and CEO, Laplace Interventional provides a device that is designed to offer an increase in life expectancy and an improvement to the quality of life to patients diagnosed with Tricuspid Regurgitation (TR). It is developing a prosthetic valve that will be delivered through through patient vasculature not requiring an open-heart surgery and thereby reducing complications in patients.
Laplace Interventional’s device is in the early stage of development phase and is NOT approved or cleared by the FDA or any other regulatory body in any region of the world.
FinSMEs
25/07/2023